Ozempic and Wegovy are injectable medications that lead to significant weight loss, but experts warn that the treatment likely needs to be ongoing to prevent a rapid rebound in weight. According to a study published in 'EClinicalMedicine', patients who stop using these medications tend to regain about 60% of the lost weight within a year, highlighting the challenges of maintaining weight loss long-term after the cessation of treatment.

The research, conducted by a team from the University of Cambridge led by Brajan Budini, analyzed six studies involving a total of 3,236 participants who used GLP-1 receptor agonists, including the active ingredient Semaglutide found in Ozempic and Wegovy. While stopping the medication often leads to rapid weight regain, the study suggests that some individuals may manage to maintain approximately 25% of their initial weight loss after discontinuing the treatment, bringing into question the effectiveness of these drugs as a sustainable weight management solution.

This information is crucial for patients considering or currently using these injections, as it reflects the importance of potentially committing to lifelong treatment to achieve and maintain weight loss related to obesity and Type 2 diabetes management. The findings also underscore the necessity for patients to adopt lifestyle changes alongside medication therapy to enhance long-term weight management and health outcomes.